The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
In this recent episode, our CEO Mark Kotter and Daniel discuss how bit.bio's synthetic biology platform industrialises the process of cell programming and produces the desired human cells in a consistent manner. They also cover bit.bio's effort to develop cell therapies and growing offering of precision reprogrammed human cells for drug development.
Listen to the episode here.
